Against the looming backdrop of patent expirations and the
need to minimise expenses the Pharma industry continues to
look towards the Asia Pacific region to outsource its’
R&D activities. As the pace of change continues to
gain momentum at an unprecedented rate it is not only the
bigger players such as China and India that are benefiting
but other countries such as Singapore, Malaysia, Taiwan
and South Korea have sought to create an infrastructure
that will support this trend through academic innovation
and government investment.
This has created a scenario where the Asia Pacific region
is becoming an increasingly attractive proposition for
fully outsourced drug discovery programmes from lead
identification through lead optimisation and beyond. This
trend has been further enhanced by a significant increase
in experts with the necessary technical expertise who had
previously worked in the West now returning to Asia to
assume leadership roles whilst still maintaining their
contacts at a global level.
Building on the success of last year's APRADOC the 2nd
congress examined the current role of the Asia Pacific
region as a potential partner for outsourcing drug
discovery programs. Focusing on discovery and
pre-clinical outsourcing the conference centred around the
key issues facing those already outsourcing R&D
efforts to Asia, looking to improve success and those in
the planning stage and therefore looking to learn best
practice techniques and strategies, critical factors, tips
and what to expect.
Through a series of interactive presentations and panel
discussions some of the topics under discussion were –
Outsourcing Strategy
Drug discovery & development outsourcing
strategies in Asia to enable high end innovation
Strategic outsourcing to increase the speed
& efficiency of drug discovery
Overcoming challenges & bottlenecks in
outsourcing to emerging Asian countries
Partnerships and alliances – how multinational
pharma companies are engaging with Asia
Comparing and contrasting outsourcing - China v
India v emerging countries
Effect of virtual pharma model outsourcing
Case study: How “big / medium / small pharma /
biotech company” successfully outsourced into Asia”
Choosing, establishing, maintaining and growing
relationships with CRO’s
What are the critical factors and essential
characteristics in establishing and maintaining
successful R&D outsourcing partnerships and
projects
Understanding cross cultural differences of
working in Asia – East v West skill sets
Panel Discussion: Future of discovery
outsourcing in Asia - Ideal requirements needed
to outsource more R&D to Asia
Panel Discussion: Challenges in Outsourcing in
Asia from a Big Pharma, Medium Pharma, Biotech &
Academic Perspective
Intellectual Property
Management and Regulations
Key IP issues when outsourcing to CRO’s in
China / Asia
Understanding Asia’s Changing IP landscape
What can and can’t be protected
Overcoming Regulatory Issues
Current status of discovery and preclinical GxP
in Asia
Good Laboratory Practice (GLP) status of Asian
countries and its implementation in non-clinical
safety studies in pharmaceutical drug development.
Scientific Focus
Building a successful CRO partnership in drug
discovery chemistry research
Building a successful CRO partnership in drug
discovery biology research
Bioanalytics, DMPK, ADME
Translational biology, pharmacology, biomarkers
Toxicology, bioinformatics, screening, data
mining
CMC outsourcing
Quality by design
CMC regulation
The 2013 Congress is under development. This year's
Advisory Board consists of:
Christopher
Bi External
Research Solutions Chemistry Lead
Pfizer
John Ellingboe Senior
Vice President, Discovery Chemistry
GVK Bio
Hans-Jürgen Federsel Senior Principal Scientist, Chemical
Science AstraZeneca
Hubert Haag Director, Global Sourcing &
External Business Opportunities Lead Generation & Candidate
Realization Sanofi-Aventis
Deutschland GmbH
Shengfang Jin Head of Strategic Outsourcing &
Senior Director Biology Agios
Pharmaceuticals Inc
Garry Pairaudeau Director, Research Outsourcing AstraZeneca
Andrew Parsons VP Preclinical Drug Development GSK
Rivka Ravid Director Brain
Bank Consultants, Senior
Scientist, Netherlands Institute
for Neurosciences Senior
Scientist, Royal Dutch Academy of
Sciences Amsterdam
Sylvie K. Sakata, PhD Head of
External Research Solutions Pfizer Inc.
La Jolla and St Louis Lead External Research
Solutions RCoE
The Agenda and speaker
list will be released in August. To receive the
first updates and get special offers before anyone else,
please complete the form below.
2012 Sponsors
Copyright: Global Engage Ltd.
Registered in England. No: 6950636
Hans-Jürgen Federsel
Shengfang Jin
Andrew Parsons
